TIDMYGEN

RNS Number : 6227O

Yourgene Health PLC

10 February 2021

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 10 February 2021 at 7.00am under RNS No 5306O.

The announcement should have stated the percentage holding following the purchase of shares by Dr John Brown as 0.049% instead of 0.49% as previously reported.

All other details remain unchanged.

The full amended text is shown below.

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Director / PDMR Shareholding

Manchester, UK - 10 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified on 9 February 2021 that Dr John Brown, a Director of the Company, purchased 102,450 Ordinary Shares of 0.10p each at a price of 12.2 pence per Ordinary Share via a pension fund held in his name on 9 February 2021.

Following this purchase, Dr John Brown holds 352,450 Ordinary Shares in the Company which represents 0.049% of the Company's issued share capital.

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                 Dr John Brown 
      -----------------------------------  ------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------- 
 a)    Position/status                      Director 
      -----------------------------------  ------------------------------------- 
 b)    Initial notification                 Initial notification 
        /Amendment 
      -----------------------------------  ------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------- 
 a)    Name                                 Yourgene Health plc 
      -----------------------------------  ------------------------------------- 
 b)    LEI                                  213800UUIT8BZE7QEH33 
      -----------------------------------  ------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------- 
 a)    Description of the                   Ordinary shares of 0.1p each 
        financial instrument, 
        type of instrument 
 
       Identification code                  ISIN: GB00BN31ZD89 
 
 b)    Nature of the transaction            Purchase 
      -----------------------------------  ------------------------------------- 
 c)    Price(s) and volume(s) 
                                            --------------------  ------------ 
                                             Price(s)              Volume(s) 
                                            --------------------  ------------ 
    12.2 pence per 
     share                                                         102,450 
   -------------------------------------------------------------  ------------ 
 
 d)    Aggregated information               N/A 
 
  - Aggregated volume 
 
  - Price 
 
 e)    Date of the transaction              9 February 2021 
      -----------------------------------  ------------------------------------- 
 f)    Place of the transaction             UK 
      -----------------------------------  -------------------------------------

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                   Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                               investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                  Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
N+1 Singer (Joint Corporate Broker)                                   Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                 Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor        Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                        Mob: 07980 541 893 / Mob: 07584 391 303

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAEAEFLAFEFA

(END) Dow Jones Newswires

February 10, 2021 05:51 ET (10:51 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Yourgene Health Charts.